Diflunisal (hereditary transthyretin amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Diflunisal (hereditary transthyretin amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code Book V

   published on

   17.02.2026

   Document type

   PDF-Dokument, 121 kB, DE, PDF

   Download file : Extract of dossier assessment (PDF-Dokument, 121 kB, DE, PDF)
2. Dossier assessment

   Diflunisal (hereditary transthyretin amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code Book V

   published on

   17.02.2026

   Document type

   PDF-Dokument, 649 kB, DE, PDF

   DOI-Link

   https://doi.org/10.60584/A25-144

   Download file : Dossier assessment (PDF-Dokument, 649 kB, DE, PDF)

Drug assessment at a glance

1. Drug assessment at a glance

   Diflunisal (hereditary transthyretin amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code Book V

   published on

   29.10.2026

   Document type

   PDF-Dokument, 201 kB, EN, PDF

   Download file : Drug assessment at a glance (PDF-Dokument, 201 kB, EN, PDF)

Dossier assessment

Project details

Project no.

A25-144

Commission

Commission awarded on 14.11.2025 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Digestion, metabolism and hormones

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-144